Mingyue Optical Lens Co.,Ltd.

SZSE:301101 Stock Report

Market Cap: CN¥6.5b

Mingyue Optical LensLtd Valuation

Is 301101 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301101 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301101 (CN¥32.55) is trading above our estimate of fair value (CN¥13.1)

Significantly Below Fair Value: 301101 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301101?

Key metric: As 301101 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301101. This is calculated by dividing 301101's market cap by their current earnings.
What is 301101's PE Ratio?
PE Ratio38x
EarningsCN¥172.13m
Market CapCN¥6.53b

Price to Earnings Ratio vs Peers

How does 301101's PE Ratio compare to its peers?

The above table shows the PE ratio for 301101 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.5x
300622 Doctorglasses ChainLtd
60x20.5%CN¥6.8b
603205 Jianerkang Medical
40.9xn/aCN¥5.5b
688029 Micro-Tech (Nanjing)Ltd
24x19.0%CN¥13.2b
688253 Innovita Biological Technology
17.1x32.4%CN¥5.7b
301101 Mingyue Optical LensLtd
38x14.5%CN¥6.5b

Price-To-Earnings vs Peers: 301101 is expensive based on its Price-To-Earnings Ratio (38x) compared to the peer average (35.5x).

Price to Earnings Ratio vs Industry

How does 301101's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
301101 38.0xIndustry Avg. 34.5xNo. of Companies17PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 301101 is expensive based on its Price-To-Earnings Ratio (38x) compared to the CN Medical Equipment industry average (36.6x).

Price to Earnings Ratio vs Fair Ratio

What is 301101's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301101 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38x
Fair PE Ratio24.5x

Price-To-Earnings vs Fair Ratio: 301101 is expensive based on its Price-To-Earnings Ratio (38x) compared to the estimated Fair Price-To-Earnings Ratio (24.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 301101 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥32.55
CN¥33.28
+2.2%
4.6%CN¥34.80CN¥31.76n/a2
Nov ’25CN¥24.86
CN¥33.28
+33.9%
4.6%CN¥34.80CN¥31.76n/a2
Oct ’25CN¥27.55
CN¥35.95
+30.5%
3.2%CN¥37.10CN¥34.80n/a2
Sep ’25CN¥26.95
CN¥35.95
+33.4%
3.2%CN¥37.10CN¥34.80n/a2
Aug ’25CN¥21.14
CN¥35.95
+70.1%
3.2%CN¥37.10CN¥34.80n/a2
Jul ’25CN¥22.59
CN¥39.05
+72.9%
5.0%CN¥41.00CN¥37.10n/a2
Jun ’25CN¥25.82
CN¥39.05
+51.2%
5.0%CN¥41.00CN¥37.10n/a2
May ’25CN¥27.22
CN¥40.20
+47.7%
2.0%CN¥41.00CN¥39.40n/a2
Apr ’25CN¥28.47
CN¥42.70
+50.0%
7.7%CN¥46.00CN¥39.40n/a2
Mar ’25CN¥30.58
CN¥42.70
+39.6%
7.7%CN¥46.00CN¥39.40n/a2
Feb ’25CN¥27.56
CN¥42.70
+54.9%
7.7%CN¥46.00CN¥39.40n/a2
Jan ’25CN¥41.86
CN¥42.70
+2.0%
7.7%CN¥46.00CN¥39.40n/a2
Dec ’24CN¥39.18
CN¥42.70
+9.0%
7.7%CN¥46.00CN¥39.40n/a2
Nov ’24CN¥36.56
CN¥42.70
+16.8%
7.7%CN¥46.00CN¥39.40CN¥24.862
Oct ’24CN¥37.68
CN¥57.23
+51.9%
0.4%CN¥57.46CN¥57.00CN¥27.552
Sep ’24CN¥36.42
CN¥57.23
+57.1%
0.4%CN¥57.46CN¥57.00CN¥26.952
Aug ’24CN¥40.46
CN¥57.03
+41.0%
0.6%CN¥57.40CN¥56.67CN¥21.142
Jul ’24CN¥41.03
CN¥57.03
+39.0%
0.6%CN¥57.40CN¥56.67CN¥22.592
Jun ’24CN¥44.74
CN¥57.03
+27.5%
0.6%CN¥57.40CN¥56.67CN¥25.822
May ’24CN¥43.99
CN¥55.03
+25.1%
4.3%CN¥57.40CN¥52.67CN¥27.222
Apr ’24CN¥37.05
CN¥51.53
+39.1%
2.2%CN¥52.67CN¥50.39CN¥28.472
Mar ’24CN¥41.23
CN¥51.53
+25.0%
2.2%CN¥52.67CN¥50.39CN¥30.582
Feb ’24CN¥42.95
CN¥51.53
+20.0%
2.2%CN¥52.67CN¥50.39CN¥27.562
Jan ’24CN¥42.01
CN¥51.53
+22.6%
2.2%CN¥52.67CN¥50.39CN¥41.862
Dec ’23CN¥38.96
CN¥51.53
+32.3%
2.2%CN¥52.67CN¥50.39CN¥39.182
Nov ’23CN¥41.37
CN¥51.53
+24.5%
2.2%CN¥52.67CN¥50.39CN¥36.562

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.7b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.53

7D

-5.8%

1Y

-34.9%

Innovita Biological Technology

CN¥5.7b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥41.72

7D

-2.1%

1Y

28.8%

Winner Medical

CN¥19.7b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.90

7D

5.4%

1Y

-14.7%